 | |
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | March 1997 |
| Founders |
|
| Headquarters | San Rafael, California, U.S. |
Key people | |
| Products | |
| Revenue |  US$2.419 billion [2] (2023) |
| US$158.1 million [2] (2023) | |
| US$167.65 million [2] (2023) | |
| Total assets | US$6,841 million [2] (2023) |
| Total equity | US$4,951 million [2] (2023) |
Number of employees | 3,401 (2023) |
| Website | biomarin |
| Footnotes / references [3][4][2] | |
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).[5][6]
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
- ^ "Leadership Team". Biomarin. Retrieved 5 December 2023.
- ^ a b c d e f "Biomarin Pharmaceutical Inc". reuters. Retrieved August 30, 2024.
- ^ "US SEC: Form 10-K BioMarin Pharmaceutical Inc". U.S. Securities and Exchange Commission. Retrieved March 31, 2018.
- ^ "BioMarin Pharmaceutical Inc. 2020 Annual Report". app.quotemedia.com. 31 December 2020. Retrieved 20 November 2021.
- ^ BruceCockburnVEVO (2011-12-15), Bruce Cockburn - Call It Democracy, archived from the original on 2021-12-19, retrieved 2019-04-18
- ^ "'A wonder drug helped me eat - then I had to go without'". 17 April 2019.